申联生物(688098) - 2020 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 34.30% to CNY 47,128,914.92 year-on-year[5] - Operating income increased by 3.81% to CNY 98,447,947.58 compared to the same period last year[5] - Basic and diluted earnings per share increased by 20.00% to CNY 0.12[5] - Total profit for Q1 2020 increased by 33.63% to ¥54,621,844.44 compared to ¥40,875,709.23 in Q1 2019, driven by effective internal management and cost-saving measures[12] - Net profit for Q1 2020 rose by 34.30% to ¥47,128,914.92 from ¥35,091,168.20 in the same period last year[18] - The company's total revenue for Q1 2020 was ¥98,447,947.58, an increase of 3.4% compared to ¥94,831,613.01 in Q1 2019[27] - The net profit for Q1 2020 reached ¥47,128,914.92, representing a 34.3% increase from ¥35,091,168.20 in Q1 2019[27] - The company reported an operating profit of ¥52,033,044.44 for Q1 2020, which is an increase from ¥40,875,849.03 in Q1 2019, reflecting a growth of 27.5%[27] Assets and Liabilities - Total assets increased by 2.64% to CNY 1,485,807,194.99 compared to the end of the previous year[5] - The total assets as of March 31, 2020, amounted to ¥1,485,807,194.99, compared to ¥1,447,626,241.87 at the end of 2019, reflecting a growth of 2.6%[24] - The total liabilities decreased to ¥155,216,514.55 in Q1 2020 from ¥166,330,556.35 in Q1 2019, a reduction of 6.7%[24] - The company's total equity increased to ¥1,330,590,680.44 in Q1 2020, up from ¥1,281,295,685.52 in Q1 2019, marking a growth of 3.8%[25] Cash Flow - Net cash flow from operating activities improved by 65.90%, reaching CNY -12,704,566.96[5] - Operating cash flow for Q1 2020 showed a net outflow of ¥12,704,566.96, an improvement of 65.90% compared to a net outflow of ¥37,260,044.16 in Q1 2019[16] - The company's cash flow from operating activities for Q1 2020 was negative at -¥12,704,566.96, an improvement from -¥37,260,044.16 in Q1 2019[31] - Cash received from sales and services in Q1 2020 was ¥39,017,636.20, significantly higher than ¥24,640,725.00 in Q1 2019, showing a growth of 58.1%[31] - Investment activities cash inflow totaled $742.13 million, while cash outflow amounted to $804.45 million, resulting in a net cash flow of -$62.33 million[32] - Financing activities generated a cash inflow of $86.42 thousand, with cash outflow of $3.70 million, leading to a net cash flow of -$3.61 million[32] - The net increase in cash and cash equivalents was -$78.64 million, decreasing the ending balance to $77.13 million[32] - The company reported a significant decrease in cash and cash equivalents compared to the previous period, which had an ending balance of $257.24 million[32] Shareholder Information - The total number of shareholders reached 11,286 at the end of the reporting period[9] - The largest shareholder, Yang Yufang, holds 21.98% of the shares, totaling 90,063,197 shares[9] - UNITED BIOMEDICAL, INC. holds 16.65% of the shares, totaling 68,230,450 shares, with some shares frozen[9] Research and Development - R&D expenditure accounted for 8.64% of operating income, an increase of 2.69 percentage points from the previous year[5] - Research and development expenses for Q1 2020 were ¥7,009,053.43, up from ¥5,639,221.22 in Q1 2019, indicating a 24.3% increase[27] Tax and Donations - The company experienced a significant increase in tax payable, rising by 1,156.55% to ¥11,720,021.45, due to accrued taxes not yet paid[12] - The company donated ¥1,411,200 worth of disinfectant to support COVID-19 prevention efforts[15] Stock Options - The company plans to grant 4,488,000 restricted stocks at a price of ¥8.8 per share to 44 incentive targets, with a total estimated accounting cost of ¥49,906,600[19] Accounting Practices - The company did not apply new revenue and lease standards for the current year, indicating stability in accounting practices[32]